MIRA Pharmaceuticals completes Phase 1 SAD for Ketamir-2; no safety issues, advances to MAD

MIRA PHARMACEUTICALS, INC.

Completed SAD phase with 32 participants across 4 cohorts (50-600 mg); no severe adverse effects observed.
Advancing to MAD phase with 3 cohorts (150, 300, 600 mg daily for 5 days) in up to 24 participants.
FDA IND clearance for neuropathic pain already received; U.S. Phase 2a trial planned for Q4 2025.
Safety monitored via C-SSRS, Bowdle VAS, and KSET scales; no clinically significant safety concerns.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.